argenx SE – ADR (NASDAQ:ARGX) had its Outperform ➝ Positive rating reiterated by Wedbush with a $121.00 price target

ME Staff
-
0

Analyst Ratings For argenx SE – ADR (NASDAQ:ARGX)

Today, Wedbush reiterated its Outperform rating on argenx SE – ADR (NASDAQ:ARGX) with a price target of $121.00.

There are 7 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on argenx SE – ADR (NASDAQ:ARGX) is Buy with a consensus target price of $141.6667 per share, a potential 51.08% upside.

Some recent analyst ratings include

  • 9/18/2018-argenx SE – ADR (NASDAQ:ARGX) had its Outperform ➝ Positive rating reiterated by Wedbush with a $121.00 price target
  • 9/17/2018-argenx SE – ADR (NASDAQ:ARGX) had its Positive ➝ Overweight rating reiterated by Piper Jaffray Companies with a $154.00 price target
  • 9/13/2018-argenx SE – ADR (NASDAQ:ARGX) has coverage initiated with a Buy rating and $139.00 price target
  • 6/29/2018-argenx SE – ADR (NASDAQ:ARGX) has coverage initiated with a Buy rating and $161.00 price target
  • 6/14/2018-argenx SE – ADR (NASDAQ:ARGX) had its Buy rating reiterated by Cowen
  • 4/8/2018-argenx SE – ADR (NASDAQ:ARGX) has coverage initiated with a Buy ➝ Buy rating and $125.00 price target


    About argenx SE – ADR (NASDAQ:ARGX)
    argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

    Recent Trading Activity for argenx SE – ADR (NASDAQ:ARGX)
    Shares of argenx SE – ADR closed the previous trading session at 93,77 −0,010 0,011 % with 99.04 shares trading hands.